The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion ...
Medpage Today on MSN6d
Continuous Parkinson's Disease Therapy Wins FDA NodAbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly ...
After being diagnosed with Parkinson's disease at 50, Janice Hall felt her tremors get worse. Three years after being diagnosed she could "feel a kind of fluttering" that her medication could not stop ...
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
Just over five years ago I was diagnosed with restless legs syndrome – my symptoms were apparently ‘typical’. The neurologist ...
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback